A Randomized, Double-Blind, Placebo-controlled, Single-center, Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to Day and Night Closed-loop Control in Patients Type 1 Diabetes (T1D)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DapaDream
- 20 Sep 2018 According to an AstraZeneca media release, data from this trial will be presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) (Oct 2018).
- 28 Feb 2018 Status changed from recruiting to completed.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.